X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Abbott India with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs GLENMARK PHARMA - Comparison Results

ABBOTT INDIA    Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA GLENMARK PHARMA ABBOTT INDIA/
GLENMARK PHARMA
 
P/E (TTM) x 41.1 25.8 159.2% View Chart
P/BV x 10.6 4.0 261.5% View Chart
Dividend Yield % 0.7 0.3 218.6%  

Financials

 ABBOTT INDIA   GLENMARK PHARMA
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-18
GLENMARK PHARMA
Mar-17
ABBOTT INDIA/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs6,110993 615.3%   
Low Rs3,996729 547.9%   
Sales per share (Unadj.) Rs1,552.2325.5 476.8%  
Earnings per share (Unadj.) Rs188.839.3 480.5%  
Cash flow per share (Unadj.) Rs196.448.7 403.6%  
Dividends per share (Unadj.) Rs55.002.00 2,750.0%  
Dividend yield (eoy) %1.10.2 468.7%  
Book value per share (Unadj.) Rs796.6159.2 500.3%  
Shares outstanding (eoy) m21.25282.17 7.5%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.32.6 123.1%   
Avg P/E ratio x26.821.9 122.1%  
P/CF ratio (eoy) x25.717.7 145.4%  
Price / Book Value ratio x6.35.4 117.3%  
Dividend payout %29.15.1 572.3%   
Avg Mkt Cap Rs m107,376242,991 44.2%   
No. of employees `0003.313.0 25.6%   
Total wages/salary Rs m3,93716,408 24.0%   
Avg. sales/employee Rs Th9,929.37,083.9 140.2%   
Avg. wages/employee Rs Th1,185.11,265.4 93.7%   
Avg. net profit/employee Rs Th1,207.7855.1 141.2%   
INCOME DATA
Net Sales Rs m32,98591,857 35.9%  
Other income Rs m1,170374 313.1%   
Total revenues Rs m34,15592,230 37.0%   
Gross profit Rs m5,24520,367 25.8%  
Depreciation Rs m1622,644 6.1%   
Interest Rs m382,373 1.6%   
Profit before tax Rs m6,21515,724 39.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-810 0.0%   
Tax Rs m2,2033,827 57.6%   
Profit after tax Rs m4,01211,088 36.2%  
Gross profit margin %15.922.2 71.7%  
Effective tax rate %35.424.3 145.6%   
Net profit margin %12.212.1 100.8%  
BALANCE SHEET DATA
Current assets Rs m22,65568,746 33.0%   
Current liabilities Rs m6,68127,027 24.7%   
Net working cap to sales %48.445.4 106.6%  
Current ratio x3.42.5 133.3%  
Inventory Days Days6585 76.2%  
Debtors Days Days2996 30.5%  
Net fixed assets Rs m83524,132 3.5%   
Share capital Rs m213282 75.3%   
"Free" reserves Rs m16,71544,643 37.4%   
Net worth Rs m16,92844,925 37.7%   
Long term debt Rs m045,363 0.0%   
Total assets Rs m24,162117,639 20.5%  
Interest coverage x163.77.6 2,146.6%   
Debt to equity ratio x01.0 0.0%  
Sales to assets ratio x1.40.8 174.8%   
Return on assets %16.811.4 146.5%  
Return on equity %23.724.7 96.0%  
Return on capital %36.919.1 192.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m36956,152 0.7%   
Fx outflow Rs m3,8078,084 47.1%   
Net fx Rs m-3,43848,068 -7.2%   
CASH FLOW
From Operations Rs m1,5276,574 23.2%  
From Investments Rs m-2,148-7,124 30.2%  
From Financial Activity Rs m-1,0245,432 -18.9%  
Net Cashflow Rs m-1,6461,992 -82.6%  

Share Holding

Indian Promoters % 0.0 48.3 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 7.9 6.9 114.5%  
FIIs % 0.1 34.4 0.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 10.5 162.9%  
Shareholders   18,270 56,727 32.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   ORCHID PHARMA LTD  WYETH LTD  TORRENT PHARMA  ALEMBIC LTD  DR. REDDYS LAB  

Compare ABBOTT INDIA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Lower, Realty and FMCG Stocks Witness Selling(Closing)

After opening the day on a positive note, share markets in India witnessed volatile trading activity and ended in red.

Related Views on News

ABBOTT INDIA Announces Quarterly Results (1QFY19); Net Profit Up 70.8% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, ABBOTT INDIA has posted a net profit of Rs 824 m (up 70.8% YoY). Sales on the other hand came in at Rs 8 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 30.1% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 30.1% YoY). Sales on the other hand came in at Rs 22 bn (down 8.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

Revenge of the Ratings Agencies(Vivek Kaul's Diary)

Sep 7, 2018

Do you remember when ratings agencies ruled financial markets? Nick explains why he thinks it's time to prepare yourselves for a comeback of the ratings agencies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Sep 19, 2018 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA 8-QTR ANALYSIS

COMPARE ABBOTT INDIA WITH

MARKET STATS